SHL general manager Frank Isaksson commented on the recent expansion activities at SHL facilities, "We have worked closely with our suppliers to design each of our facilities for maximum scalability. Just recently we added several new lines of molding machines and also installed additional material handling systems. In fact, our facility management team will have new production areas set up for expansion well in advance of receiving any equipment. And, based on our experience, will always be expanding our molding and material handling systems, in addition to tooling, metrology and automation. Knowing this now, we can prepare in advance."
"The teams involved in these areas are experienced and always looking into ways to optimize production and introduce new technologies to maximize output," he added. "In addition, we continue to invest heavily in employee-centric training programs for experienced staff and newcomers, as well as forward-looking intern and apprentice programs."
What all this means to biopharmaceutical customers is that SHL will have the capacity to produce auto injectors, pen injectors and inhaler systems even if demand increases beyond initial forecasts. Communication between all partners is vital regarding ongoing forecasts, especially with several injectable biologics commanding valuations in the several billions USD.